About Us
Our Mission
Archerfish Precision Diagnostics is dedicated to improving patient care by offering cutting-edge diagnostic solutions to doctors.
Levering on our robust capabilities in development and commercialisation, we consistently innovate to address the changing requirements of the regional healthcare ecosystem.
We Believe in
The Power of a Team
Dr Lim Cheok Peng
Chairman
Mr Peter Chia
Director
Dr Cheong Wei Yang
Director
Dr. Lim Cheok Peng, a respected cardiologist, is the co-founder of Angsana Laboratory. He was previously the CEO of Parkway Holdings and Managing Director of IHH Healthcare Berhad. His extensive experience cements his influence in the private healthcare sector.
Mr. Peter Chia is the Director and Chief Executive Officer at Temasek Life Sciences Laboratory and Temasek Life Sciences Accelerator (TLA). He plays a key role in the establishment of many significant research collaborations with the industry, the commercialisation of TLL research technologies and creation of spin-offs.
Dr Cheong Wei Yang is serving as Senior Adviser at the Ministry of Health Health Economics division. He formulates health economics models for new technologies in collaboration with academia. He also hold the position of Vice Provost (Strategic Research Partnerships) at Singapore Management University, where they develop and implement strategic research partnerships with government and industry. Dr Cheong's expertise bridges the gap between academic research, government policy, and industry innovation.
Dr Ian Cheong
Director
Dr Chris Tan
Group Chief Executive Officer
Mr Kevin Lee
Group Chief Financial Officer
Dr. Ian Cheong is a pioneering scientist and entrepreneur, co-founding Pathnova Laboratories to revolutionise nasopharyngeal cancer detection through AI-enhanced serology, currently demonstrated in a large-scale Singaporean study. His innovative work spans multiple domains, including developing a novel algorithmic approach for cancer mutation identification and discovering a unique tumor-targeting bacterial property for chemotherapy delivery. A distinguished researcher, he holds a PhD from Johns Hopkins and has received numerous awards, reflecting his significant contributions to molecular pathogenesis, genetics, genomics, and cancer therapeutics.
Dr Chris Tan is the Group CEO of Archerfish DX and co-founder of Angsana Laboratory. Under his stewardship for Angsana, he grew the business to become the leading molecular oncology provider in Asia and achieved CAP accreditation. He is a seasoned executive with a strong track record in the life sciences and diagnostics sectors, demonstrated by leadership roles at companies like SomaLogic, and Twist Bioscience. He has a proven ability to build and scale commercial operations in the APAC region, including establishing new entities and driving significant revenue growth.
Kevin Lee is the Group CFO of Archerfish Precision Diagnostics. He is concurrently the CEO of Angsana Molecular & Diagnostics Laboratory. Kevin was also previously Group COO and CFO of various regional healthcare groups where he was responsible for the overall strategy and direction of the business. Prior to taking his healthcare leadership roles, Kevin also spent more than 20 years in investment banking and strategy consulting. Kevin is a Fellow Chartered Accountant, an ASEAN CPA and holds an MBA from Warwick Business School, UK. Kevin is also on the board of Renal Health Services Limited, a charity that supports kidney health in Singapore, and on the finance committee of Catholic Pre-school Education (Singapore) Ltd, a non-profit that manages preschools in Catholic parishes.
Our History
Fo​rmed in 2025, Archerfish Precision Diagnostics was incepted from the strategic merger of two industry leaders: Angsana Molecular and Diagnostics Laboratory and Pathnova Laboratories.
Angsana is a pioneer in the field of molecular oncology in Asia, having introduced clinical Next-Generation Sequencing (NGS) early on. They have a strong track record of successful commercialisation and bringing clinical diagnostics tests to the market. PathNova specialises in the development and manufacturing of diagnostic products, including the creation of intellectual property related to novel diagnostic technologies, exemplified by their proprietary early screening test for nasopharyngeal cancer.
​
Recognising the immense potential for synergy, these two powerhouses joined forces, creating a unified entity with a clear vision: to address the specific healthcare needs of the Asian community. This merger was not merely a consolidation of resources; it was a fusion of expertise, a blending of innovation and commercial acumen. Archerfish DX, built on the foundations of Angsana's commercial success and Pathnova's scientific excellence, is now dedicated to accelerating the development and accessibility of affordable diagnostics, ensuring that the fruits of scientific advancement reach the patients who need them most across Asia.
Our Facilities
Angsana Molecular & Diagnostics Laboratory
67 Ubi Avenue 1, #06-06,
Starhub Green North Wing, Singapore 408942
